TNF and cancer: This privation of effector function involves the loss of TNF-α, IFN-γ [519] and high levels of PD-1, as reported in several human cancers such as melanoma [395] (Table 2), NSCLC [520], HNSCC [521], gastric cancer [522] and ovarian cancer [523].